ERR2208968
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- SPERMATOGENESIS+0.300
- MYC_TARGETS_V2+0.200
- OXIDATIVE_PHOSPHORYLATION+0.200
- PANCREAS_BETA_CELLS+0.200
- CHOLESTEROL_HOMEOSTASIS+0.100
- FATTY_ACID_METABOLISM+0.100
- KRAS_SIGNALING_DN+0.100
- MTORC1_SIGNALING+0.100
- MYC_TARGETS_V1+0.100
- UNFOLDED_PROTEIN_RESPONSE+0.100
Top 10 suppressed
- IL6_JAK_STAT3_SIGNALING-0.500
- TNFA_SIGNALING_VIA_NFKB-0.500
- ALLOGRAFT_REJECTION-0.400
- IL2_STAT5_SIGNALING-0.400
- INFLAMMATORY_RESPONSE-0.400
- INTERFERON_GAMMA_RESPONSE-0.400
- KRAS_SIGNALING_UP-0.400
- ANGIOGENESIS-0.300
- APICAL_JUNCTION-0.300
- APOPTOSIS-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR23303740 | — | — | 0.874 |
| 2 | SRR33532828 | — | B | 0.874 |
| 3 | R16 | — | — | 0.871 |
| 4 | TCGA-E5-A4U1-01A-11R-A31N-07 | — | — | 0.870 |
| 5 | GSM5359425 | — | — | 0.864 |
| 6 | SRR5088853 | — | — | 0.864 |
| 7 | BS_DGTPWJ59 | Neurocytoma | — | 0.863 |
| 8 | SRR1072504 | GTEX | — | 0.860 |
| 9 | SRR8518209 | — | C | 0.860 |
| 10 | SRR1386818 | GTEX | — | 0.853 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| SPERMATOGENESIS | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.200 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.100 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.100 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.100 | Idelalisib | — uncovered |